

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application.

**Listing of Claims:**

1. (Currently amended) A targeting moiety comprising a conjugate of an antibody linked to a ligand-binding region of ~~a receptor subunit selected from the group consisting of interleukin-2 receptor  $\alpha$  (IL-2R $\alpha$ ), interleukin-4 receptor  $\alpha$  (IL-4R $\alpha$ ), and interleukin-15 receptor  $\alpha$  (IL-15R $\alpha$ ),~~ wherein the said antibody comprising antigen-binding variable region domains is specific for a cell marker specific to a targeted cell.
2. (Original) A targeting moiety as claimed in claim 1, comprising a covalent conjugate in which the antibody is covalently linked to the ligand-binding region of the receptor.
3. (Original) A targeting moiety as claimed in claim 1, comprising a fusion protein of the antibody and the ligand-binding region.
- 4-5. (Canceled)
6. (Previously presented) A targeting moiety as claimed in claim 1, wherein the antibody is specific to human leukocyte antigen-DR (HLA-DR).
- 7-10. (Canceled)
11. (Previously presented) A targeting moiety as claimed in claim 1, wherein the antibody is specific to human leukocyte antigen-DR (HLA-DR) and is linked to the ligand-binding region of IL-4R $\alpha$ .
- 12-19 (Canceled)
20. (Original) A composition comprising a targeting moiety according to claim 1, and a pharmaceutically acceptable carrier.
- 21-36. (Canceled)
37. (Original) A targeting moiety comprising a conjugate of an antibody linked to a ligand-binding region of interleukin-13 receptor  $\alpha$  (IL-13R $\alpha$ ), which antibody is specific to HLA-DR.
38. (Canceled)